Christopher J. Bakkenist

Christopher J. Bakkenist

Auto-generated profile, based on publicly available information

Christopher J. Bakkenist

Department of Radiation Oncology, School of Medicine University of Pittsburgh Pittsburgh Pennsylvania USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
FVFrank P. Vendetti
Frank P. Vendetti
ALAlan Lau
Alan Lau
SSSandra Schamus
Sandra Schamus
TCThomas P. Conrads
Thomas P. Conrads
MOMark J. O’connor
Mark J. O’connor
CBChristopher J. Bakkenist
Christopher J. Bakkenist
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo

13 August 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
FVFrank P. Vendetti
Frank P. Vendetti
PKPooja Karukonda
Pooja Karukonda
DCDavid A. Clump
David A. Clump
TTTroy Teo
Troy Teo
RLRonald Lalonde
Ronald Lalonde
CBChristopher J. Bakkenist
Christopher J. Bakkenist
DNA-damaging chemotherapy and radiation therapy are integrated into the treatment paradigm of the majority of cancer patients. Recently, immunotherapy that targets the immunosuppressive interaction between programmed death 1 (PD-1) and its ligand PD-L1 has been approved for malignancies including non–small cell lung cancer, melanoma, and head and neck squamous cell carcinoma. ATR is a DNA damage–signaling kinase activated at damaged replication forks, and ATR kinase inhibitors potentiate the cytotoxicity of DNA-damaging chemotherapies. We show here that the ATR kinase inhibitor AZD6738 combines with conformal radiation therapy to attenuate radiation-induced CD8+ T cell exhaustion and potentiate CD8+ T cell activity in mouse models of Kras-mutant cancer. Mechanistically, AZD6738 blocks radiation-induced PD-L1 upregulation on tumor cells and dramatically decreases the number of tumor-infiltrating Tregs. Remarkably, AZD6738 combines with conformal radiation therapy to generate immunologic memory in complete responder mice. Our work raises the possibility that a single pharmacologic agent may enhance the cytotoxic effects of radiation while concurrently potentiating radiation-induced antitumor immune responses.

17 June 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
TMTatiana Moiseeva
Tatiana Moiseeva
YYYandong Yin
Yandong Yin
MCMichael J. Calderon
Michael J. Calderon
CQChenao Qian
Chenao Qian
SSSandra Schamus-Haynes
Sandra Schamus-Haynes
CBChristopher J. Bakkenist
Christopher J. Bakkenist
DNA damage-induced signaling by ATR and CHK1 inhibits DNA replication, stabilizes stalled and collapsed replication forks, and mediates the repair of multiple classes of DNA lesions. We and others have shown that ATR kinase inhibitors, three of which are currently undergoing clinical trials, induce excessive origin firing during unperturbed DNA replication, indicating that ATR kinase activity limits replication initiation in the absence of damage. However, the origins impacted and the underlying mechanism(s) have not been described. Here, we show that unperturbed DNA replication is associated with a low level of ATR and CHK1 kinase signaling and that inhibition of this signaling induces dormant origin firing at sites of ongoing replication throughout the S phase. We show that ATR and CHK1 kinase inhibitors induce RIF1 Ser2205 phosphorylation in a CDK1-dependent manner, which disrupts an interaction between RIF1 and PP1 phosphatase. Thus, ATR and CHK1 signaling suppresses CDK1 kinase activity throughout the S phase and stabilizes an interaction between RIF1 and PP1 in replicating cells. PP1 dephosphorylates key CDC7 and CDK2 kinase substrates to inhibit the assembly and activation of the replicative helicase. This mechanism limits origin firing during unperturbed DNA replication in human cells.

13 April 2005 in Cell Cycle
Verified
Journal Article
Closed access
PDF file
JBJirina Bartkova
Jirina Bartkova
CBChristopher J. Bakkenist
Christopher J. Bakkenist
EMEwa Rajpert-De Meyts
Ewa Rajpert-De Meyts
NSNiels E. Skakkebæk
Niels E. Skakkebæk
MSMaxwell Sehested
Maxwell Sehested
JBJiri Bartek
Jiri Bartek
The ATM kinase is a tumor suppressor and key regulator of biological responses to DNA damage. Cultured cells respond to genotoxic insults that induce DNA double-strand breaks by prompt activation of ATM through its autophosphorylation on serine 1981. However, whether ATM-S1981 becomes phosphorylated in vivo, for example during physiological processes that generate DSBs, is unknown. Here we produced phosphospecific monoclonal antibodies against S1981-phosphorylated ATM (pS-ATM), and applied them to immunohistochemical analyses of a wide range of normal human tissues and testicular tumors. Our data show that regardless of proliferation and differentiation, most human tissues contain only the S1981-nonphosphorylated, inactive form of ATM. In contrast, nuclear staining for pS-ATM was detected in subsets of bone-marrow lymphocytes and primary spermatocytes in the adult testes, cell types in which DSBs are generated during physiological V(D)J recombination and meiotic recombination, respectively. Among testicular germ-cell tumors, an aberrant constitutive pS-ATM was observed especially in embryonal carcinomas, less in seminomas, and only modestly in teratomas and the pre-invasive carcinoma-in-situ stage. Compared with pS-ATM, phosphorylated histone H2AX (?H2AX), another DNA damage marker and ATM substrate, was detected in a higher proportion of cancer cells, and also in normal fetal gonocytes, and a wider range of adult spermatocyte differentiation stages. Collectively, our results strongly support the physiological relevance of the recently proposed model of ATM autoactivation, and provide further evidence for constitutive activation of the DNA damage machinery during cancer development. The new tools characterized here should facilitate monitoring of ATM activation in clinical specimens, and help develop future treatment strategies.

9 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
TMTatiana Moiseeva
Tatiana Moiseeva
BHBrian Hood
Brian Hood
SSSandy Schamus
Sandy Schamus
MOMark J. O’connor
Mark J. O’connor
TCThomas P. Conrads
Thomas P. Conrads
CBChristopher J. Bakkenist
Christopher J. Bakkenist
ATR kinase activity slows replication forks and prevents origin firing in damaged cells. Here we describe proteomic analyses that identified mechanisms through which ATR kinase inhibitors induce unscheduled origin firing in undamaged cells. ATR-Chk1 inhibitor-induced origin firing is mediated by Cdc7 kinase through previously undescribed phosphorylations on GINS that induce an association between GINS and And-1. ATR-Chk1 inhibitor-induced origin firing is blocked by prior exposure to DNA damaging agents showing that the prevention of origin firing does not require ongoing ATR activity. In contrast, ATR-Chk1 inhibitor-induced origins generate additional replication forks that are targeted by subsequent exposure to DNA damaging agents. Thus, the sequence of administration of an ATR kinase inhibitor and a DNA damaging agent impacts the DNA damage induced by the combination. Our experiments identify competing ATR and Cdc7 kinase-dependent mechanisms at replication origins in human cells.

14 September 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
AGArmin Gamper
Armin Gamper
RRReza Rofougaran
Reza Rofougaran
SWSimon C. Watkins
Simon C. Watkins
JGJoel S. Greenberger
Joel S. Greenberger
JBJan H. Beumer
Jan H. Beumer
CBChristopher J. Bakkenist
Christopher J. Bakkenist
The kinase ATR is activated by RPA-coated single-stranded DNA generated at aberrant replicative structures and resected double strand breaks. While many hundred candidate ATR substrates have been identified, the essential role of ATR in the replicative stress response has impeded the study of ATR kinase-dependent signalling. Using recently developed selective drugs, we show that ATR inhibition has a significantly more potent effect than ATM inhibition on ionizing radiation (IR)-mediated cell killing. Transient ATR inhibition for a short interval after IR has long-term consequences that include an accumulation of RPA foci and a total abrogation of Chk1 S345 phosphorylation. We show that ATR kinase activity in G1 phase cells is important for survival after IR and that ATR colocalizes with RPA in the absence of detectable RPA S4/8 phosphorylation. Our data reveal that, unexpectedly, ATR kinase inhibitors may be more potent cellular radiosensitizers than ATM kinase inhibitors, and that this is associated with a novel role for ATR in G1 phase cells.